CMPS retraces at least half its 15% gain (below ~$12.65) within 3 weeks absent a disclosed Phase 3 psilocybin catalyst.

A company called Compass Pathways (ticker: CMPS) saw its stock jump about 15%, but other psychedelic companies didn't move alongside it — which usually means the jump was driven by hype or short-term trading rather than a real change in the company's prospects. When that happens, stocks typically fall back down to where they started within a few weeks, especially if no major news (like strong results from a large Phase 3 trial) comes out to justify the higher price.

Idiosyncratic pops without cross-sector confirmation mean-revert. ATAI/MMED not participating confirms no fundamental re-rating.